Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

ClinicalTrials.gov ID: NCT05879107

Public ClinicalTrials.gov record NCT05879107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\xa0Years and Older

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.

Study identification

NCT ID
NCT05879107
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,113 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 26, 2023 (Actual)
Primary completion
Dec 6, 2023 (Actual)
Completion
May 7, 2024 (Actual)
Last update posted
May 18, 2025

2023 – 2024

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
20
Facility City State ZIP Site status
GSK Investigational Site Guntersville Alabama 35976 —
GSK Investigational Site Phoenix Arizona 85023 —
GSK Investigational Site Huntington Beach California 92647 —
GSK Investigational Site Modesto California 95350 —
GSK Investigational Site Hamden Connecticut 06517 —
GSK Investigational Site Clearwater Florida 33756 —
GSK Investigational Site DeLand Florida 32720 —
GSK Investigational Site Jupiter Florida 33458 —
GSK Investigational Site Largo Florida 33777 —
GSK Investigational Site Orlando Florida 32801 —
GSK Investigational Site West Des Moines Iowa 50266 —
GSK Investigational Site New Orleans Louisiana 70115 —
GSK Investigational Site Troy Michigan 48085 —
GSK Investigational Site St Louis Missouri 63110 —
GSK Investigational Site Cincinnati Ohio 45212 —
GSK Investigational Site North Charleston South Carolina 29405 —
GSK Investigational Site Dallas Texas 75251 —
GSK Investigational Site Frisco Texas 75033 —
GSK Investigational Site Mesquite Texas 75149 —
GSK Investigational Site Plano Texas 75024 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05879107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 18, 2025 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05879107 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →